Open AccessIntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab—pharmacokinetic modeling to optimize therapeutic index
Author(s) -
Rahul S. Yerrabelli,
Ping He,
Edward K. Fung,
Kim Krämer,
Pat Zanzonico,
John L. Humm,
Hong-Fen Guo,
Neeta PanditTaskar,
Steven M. Larson,
NaiKong V. Cheung
Publication year - 2020
Publication title -
european journal of nuclear medicine and molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.313
H-Index - 163
eISSN - 1619-7089
pISSN - 1619-7070
DOI - 10.1007/s00259-020-05050-z
Subject(s) - pharmacokinetics , radioimmunotherapy , therapeutic index , medicine , toxicity , area under the curve , pharmacology , nuclear medicine , antibody , monoclonal antibody , drug , immunology
Radioimmunotherapy (RIT) delivered through the cerebrospinal fluid (CSF) has been shown to be a safe and promising treatment for leptomeningeal metastases. Pharmacokinetic models for intraOmmaya antiGD2 monoclonal antibody 131 I-3F8 have been proposed to improve therapeutic effect while minimizing radiation toxicity. In this study, we now apply pharmacokinetic modeling to intraOmmaya 131 I-omburtamab (8H9), an antiB7-H3 antibody which has shown promise in RIT of leptomeningeal metastases.